Glyphosate-based weed killers like RoundUp have become the most widely used in the world, growing 100-fold since their introduction and creating billions in annual sales for chemical giant Monsanto in the process.
However, recent studies suggest this chemical, used by everyone from weekend gardeners to professional landscapers and agriculture workers, may lead to a dangerous form of cancer called non-Hodgkin’s lymphoma.
Every parent knows how stubborn babies can be when it comes to eating, napping on schedule and the ill-fated timing of those, err blowouts.
Last year, Stryker-owned Howmedica Osteonics Corp. recalled more than 40,000 of its popular hip replacement implants from the market due to defects in the LFit femoral head that can cause devices to fail, break, or shed metal debris in patients.
However, this is only the latest in a string of recalls by the company of their hip devices for similar problems, and they have already paid more than $1 billion in compensation to those injured.
The shocking reports out last month linking breast implants to a rare form of cancer caught many of us by surprise. After all, with nearly 300,000 women undergoing breast augmentation each year, most of us know someone who’s had an implant procedure.
Anytime a risk of cancer is involved, it should get our full attention. But, as we dig deeper into this latest health alert, we find it isn’t necessarily new and may not pose as great a risk as has been portrayed by the headlines. And, those injured may have legal options.
If you or a loved one are among the more than 250,000 people who undergo heart surgery each year, chances are doctors used a device called a surgical heater-cooler to maintain blood temperature at a constant bodily level during the procedure.
Recently, the FDA and CDC warned that the surgical heater brand used in most heart surgeries each year, the Stockert 3T Heater-Cooler, could subject patients to deadly internal infections.
In December, medical device giant Zimmer Biomet issued what has become a Class-I recall of one of their most popular shoulder implants, the Comprehensive Reverse Shoulder. However, the company did so without notifying the thousands of patients that had received the devices.
Now, many are questioning the company’s handling of the recall, and asking if Zimmer could have done more to protect patients from potential implant failures and the need for painful revision surgery.
With the use of oral anticoagulants growing rapidly, the debate rages on about whether these drugs have a net positive effect or carry risks that outweigh the benefits.
Last week, the maker of Xarelto touted the results of a new study showing the drug may reduce the occurrence of major cardiac events. This came on the heels of a consumer safety group warning of increased dangers of internal bleeding from the entire class of blood thinners that also includes Pradaxa and Eliquis.
A leading consumer drug safety advocate warned last week that a popular class of drugs designed to treat hepatitis C may carry significant risks for liver damage and death, DrugNews has learned.
The report comes just months after the FDA itself issued a different warning on the new class of Hep C drugs, called direct-acting antivirals, that they may cause a return of Hepatitis B.
In recent months, orthopedic device maker Stryker has warned doctors that several models of its metal hip implants may be defective, causing device separation, failure and the need for revision surgery.
This was followed by a mandatory Stryker hip recall in Canada last September due to a higher than expected number of patient complaints.
Abdominal hernias are a common injury that will affect more than 25% of all men and even some women during their lifetime. And, for the most part, they are resolved with a simple surgery. Each year, more than 350,000 people in the United States undergo hernia repair procedures.
Hernia repair may be performed with only sutures. However, for over 50 years, doctors have done most hernia repairs with a lightweight plastic mesh that bonds to the abdominal wall with scar tissue to add strength.
With a blood thinner market estimated at over $6 billion per year, three manufacturers have been fighting it out to get their drugs – Pradaxa, Xarelto and Eliquis – prescribed to as many patients as possible.
Never mind that these drugs have been linked to serious internal bleeding and death; or that, to this day, thousands of lawsuits have been filed and billions of dollars will be paid out to victims. The makers are determined to increase their market share by any means necessary.